Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nuvectis Pharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
NVCT
Nasdaq
2834
www.nuvectis.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nuvectis Pharma, Inc.
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
- Feb 7th, 2025 1:30 pm
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
- Feb 5th, 2025 2:01 pm
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
- Feb 4th, 2025 9:05 pm
Favourable Signals For Nuvectis Pharma: Numerous Insiders Acquired Stock
- Feb 4th, 2025 12:23 pm
Insiders hold 63% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently
- Jan 4th, 2025 2:14 pm
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
- Dec 10th, 2024 1:00 pm
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- Nov 25th, 2024 2:55 pm
Nuvectis Pharma reports data from Phase 1b study of NXP800
- Nov 15th, 2024 12:45 pm
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
- Nov 14th, 2024 7:23 pm
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Nov 14th, 2024 12:00 pm
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why
- Nov 13th, 2024 1:50 pm
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
- Nov 7th, 2024 2:55 pm
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
- Nov 5th, 2024 12:00 pm
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
- Oct 28th, 2024 12:21 pm
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
- Oct 23rd, 2024 12:00 pm
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
- Oct 7th, 2024 12:00 pm
Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
- Sep 24th, 2024 11:13 am
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
- Sep 16th, 2024 11:15 am
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 5th, 2024 12:00 pm
Nuvectis’ NXP800 gains FDA ODD for cancer treatment
- Aug 30th, 2024 10:52 am
Scroll